Psyence Biomedical Ltd. Files Interim Financials

TL;DR

Psyence Biomedical dropped its Q2/Q3 financials on 11/20. Check the numbers.

AI Summary

Psyence Biomedical Ltd. filed a Form 6-K on November 20, 2025, to report its unaudited interim consolidated financial statements for the three and six months ended September 30, 2025. The company is a foreign private issuer based in Toronto, Ontario, and files annual reports under Form 20-F.

Why It Matters

This filing provides investors with an update on Psyence Biomedical's financial performance for the recent interim period, crucial for assessing the company's operational health and investment potential.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not contain new material events or significant financial changes.

Key Players & Entities

• Psyence Biomedical Ltd. (company) — Registrant
• November 20, 2025 (date) — Filing Date
• September 30, 2025 (date) — Reporting Period End Date
• Toronto, Ontario (location) — Company Headquarters

FAQ

Filing Documents

• ea0265913-6k_psyence.htm (6-K) — 15KB
• ea026591301ex99-1_psyence.htm (EX-99.1) — 555KB
• ea026591301ex99-2_psyence.htm (EX-99.2) — 35KB
• ex99-1_001.jpg (GRAPHIC) — 37KB
• ex99-1_002.jpg (GRAPHIC) — 7KB
• ex99-2_001.jpg (GRAPHIC) — 37KB
• ex99-2_002.jpg (GRAPHIC) — 7KB
• 0001213900-25-113106.txt ( ) — 3957KB
• pbm-20250930.xsd (EX-101.SCH) — 68KB
• pbm-20250930_cal.xml (EX-101.CAL) — 30KB
• pbm-20250930_def.xml (EX-101.DEF) — 235KB
• pbm-20250930_lab.xml (EX-101.LAB) — 427KB
• pbm-20250930_pre.xml (EX-101.PRE) — 246KB
• ea0265913-6k_psyence_htm.xml (XML) — 445KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant's name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Explanatory Note Psyence Biomedical Ltd. (the "Company") is filing this Form 6-K to file its unaudited interim consolidated financial statements for the three and six months ended September 30, 2025 and 2024 (the "Interim Financial Statements"), along with its corresponding Management's Discussion and Analysis. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Unaudited Condensed Consolidated Financial Statements for the Three and Six Months Ended September 30, 2025 and 2024. 99.2 Management Discussion and Analysis for the Unaudited Condensed Consolidated Financial Statements for the Three and Six Months Ended September 30, 2025 and 2024. 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: November 20, 2025 Psyence Biomedical Ltd. By: /s/ Jody Aufrichtig Name: Jody Aufrichtig Title: Chief Executive Officer and Director 3

View Full Filing

View this 6-K filing on SEC EDGAR